Business context and reporting period
The supplied filing is ITUS Corporation’s unaudited Form 10-Q for the quarter and six months ended April 30, 2015; it identifies the registrant as ITUS Corporation, not Anixa Biosciences Inc. ITUS described its business as developing, acquiring, and licensing emerging technologies, including thin-film displays, encrypted communications, and advanced materials.
Financial performance and position
- Six months ended April 30, 2015: Revenue was $9.16 million, including a $9.0 million AU Optronics (AUO) settlement and $160,000 of patent licensing revenue. Operating income was $1.72 million and net income was $1.52 million, or $0.01 per basic and diluted share.
- Three months ended April 30, 2015: Revenue was $25,000, operating loss was $2.13 million, and net loss was $2.24 million, or $0.01 per share.
- Cash flow, six months: Operating activities provided $2.87 million; investing activities provided $45,224; financing activities used $200,000. Cash and cash equivalents rose to $6.08 million from $3.36 million at October 31, 2014.
- Liquidity: Cash, cash equivalents, and short-term certificates of deposit totaled approximately $8.48 million at April 30, 2015. Current assets were $8.52 million and current liabilities were $688,676.
- Obligations: Total liabilities were $4.14 million, including a $3.45 million patent acquisition obligation. The filing reported no convertible debentures outstanding as of October 31, 2014.
- Equity and costs: Shareholders’ equity was $6.99 million. Six-month marketing, general, and administrative expense included $1.56 million of non-cash stock-option compensation.
Material changes versus the prior comparable period
- Six-month revenue rose from $1.11 million to $9.16 million, chiefly because of the $9.0 million AUO settlement. Patent licensing revenue fell to $160,000 from $1.11 million.
- Six-month results improved from a $6.86 million net loss to $1.52 million net income. The comparison also reflects the prior-year $2.31 million derivative-liability loss and $483,000 loss on extinguishment of debt, neither of which recurred.
- Litigation and licensing expense increased to $3.44 million from $104,000, primarily in connection with the AUO settlement. Interest expense decreased to $218,000 from $801,000.
- For the second quarter alone, revenue fell to $25,000 from $1.11 million and net loss narrowed to $2.24 million from $3.25 million.
- The company repurchased 800,000 common shares and canceled warrants for 400,000 shares for $200,000. It also repriced 54.6 million employee, officer, and director options to an exercise price of $0.103, recording approximately $297,000 of incremental compensation expense.
Outlook, commentary, and risks
Management stated that, based on information available May 22, 2015, cash, short-term investments, and expected cash flows should fund operations for at least 12 months. This is an estimate, not a guarantee. Management cautioned that future cash flows may differ from projections; additional equity or convertible-debt financing could dilute shareholders, and unavailable financing or insufficient expense reductions could require curtailing or ceasing operations.
The AUO settlement resolved litigation over joint development and commercialization of display technologies; ITUS received $9.0 million and transferred certain electrophoretic-display patents. The company said it continued licensing encrypted-communications and advanced-materials patents and had resumed its Nano field-emission display development program. Patent acquisition obligations were due no later than November 2017, with the final payment at the company’s option in cash or common stock, and subject to reduction by royalties paid. The filing reported no material changes to previously disclosed risk factors and no material pending legal proceedings beyond ordinary-course matters and patent-enforcement suits.
Important facts for investors to verify
- Confirm the issuer and filing identity: the supplied document names ITUS Corporation, although the request names Anixa Biosciences Inc.
- Assess how much of reported income and liquidity depended on the nonrecurring $9.0 million AUO settlement, given the low current-period patent licensing revenue.
- Review the settlement-related expense detail and the transferred patents’ implications for future licensing and development opportunities.
- Verify the terms, timing, and potential cash-versus-stock settlement of the $3.45 million patent acquisition obligation.
- Evaluate potential dilution from outstanding options and warrants, the option repricing, and any future financing needs.
- Compare management’s 12-month liquidity expectation with subsequent operating cash flows and actual financing or spending plans.